Literature DB >> 20721834

Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases.

William Langridge1, Béla Dénes, István Fodor.   

Abstract

Parenteral vaccination is generally considered to be the most effective form of therapy for protection against infectious diseases. In recent years, vaccination at mucosal surfaces and combinatorial vaccination strategies that link immunostimulatory molecules to antigens have been developed to enhance vaccine efficacy. Prominent among immunological enhancement strategies are the bacterial A and B toxins, which include the cholera toxin (CT)A and CTB subunits. In contrast to the toxic CTA subunit, the non-toxic CTB subunit displays both carrier and immunostimulatory properties. When linked to pathogen antigens, CTB can impart immunostimulatory properties that are characteristic of the linked antigen. Vaccination strategies have also been broadened to include 'self' proteins applied for the immunological suppression of autoimmunity. When CTB is linked to an autoantigen, the outcome might be considered paradoxical. In type 1 diabetes, self proteins become strongly immunosuppressive, while cancer CTB-autoantigen fusion proteins may exert a strong inflammatory response. This review discusses the immunostimulatory and immunosuppressive roles played by the CTB subunit in vaccine protection and therapy against infectious and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721834

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  15 in total

1.  Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B.

Authors:  Han Lei; Zhina Sheng; Qian Ding; Jian Chen; Xiaohui Wei; Dominic Man-Kit Lam; Yuhong Xu
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

Review 2.  Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies.

Authors:  Sodiq A Hameed; Stephane Paul; Giann Kerwin Y Dellosa; Dolores Jaraquemada; Muhammad Bashir Bello
Journal:  NPJ Vaccines       Date:  2022-06-28       Impact factor: 9.399

Review 3.  Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.

Authors:  George Hajishengallis; Terry D Connell
Journal:  Vet Immunol Immunopathol       Date:  2012-09-26       Impact factor: 2.046

Review 4.  Current status of viral expression systems in plants and perspectives for oral vaccines development.

Authors:  Jorge A Salazar-González; Bernardo Bañuelos-Hernández; Sergio Rosales-Mendoza
Journal:  Plant Mol Biol       Date:  2015-01-06       Impact factor: 4.335

5.  Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.

Authors:  Simon H Bridge; Sally A Sharpe; Mike J Dennis; Stuart D Dowall; Brian Getty; Donald S Anson; Michael A Skinner; James P Stewart; Tom J Blanchard
Journal:  Virol J       Date:  2011-09-07       Impact factor: 4.099

6.  Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice.

Authors:  Upendra K Kar; Janina Jiang; Cheryl I Champion; Sahar Salehi; Minu Srivastava; Sherven Sharma; Shahrooz Rabizadeh; Kayvan Niazi; Valerie Kickhoefer; Leonard H Rome; Kathleen A Kelly
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

7.  The Corn Smut ('Huitlacoche') as a New Platform for Oral Vaccines.

Authors:  Margarita Juárez-Montiel; Andrea Romero-Maldonado; Elizabeth Monreal-Escalante; Alicia Becerra-Flora; Schuyler S Korban; Sergio Rosales-Mendoza; Juan Francisco Jiménez-Bremont
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

8.  Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.

Authors:  Juliette K Tinker; Jie Yan; Reece J Knippel; Panos Panayiotou; Kenneth A Cornell
Journal:  Toxins (Basel)       Date:  2014-04-22       Impact factor: 4.546

9.  Dendritic Cell-Mediated Mechanisms Triggered by LT-IIa-B5, a Mucosal Adjuvant Derived from a Type II Heat-Labile Enterotoxin of Escherichia coli.

Authors:  Chang Hoon Lee; George Hajishengallis; Terry D Connell
Journal:  J Microbiol Biotechnol       Date:  2017-04-28       Impact factor: 2.351

10.  Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro.

Authors:  Priya Saikumar Lakshmi; Dheeraj Verma; Xiangdong Yang; Bethany Lloyd; Henry Daniell
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.